Inhaled hexadecyl-treprostinil provides pulmonary vasodilator activity at significantly lower plasma concentrations than infused treprostinil
- PMID: 29421665
- DOI: 10.1016/j.pupt.2018.02.002
Inhaled hexadecyl-treprostinil provides pulmonary vasodilator activity at significantly lower plasma concentrations than infused treprostinil
Abstract
INS1009 is a long acting pulmonary vasodilator prodrug of treprostinil (TRE) that is formulated in a lipid nanoparticle for inhaled delivery by nebulization. This study examined the ability of INS1009 to inhibit vasoconstriction in the pulmonary vasculature of rats and dogs and the extent to which local activity within the lung contributes to its activity. Rats received a single dose of INS1009 by nose-only inhalation or were given a continuous intravenous (i.v.) infusion of TRE, followed by an i.v. challenge of the thromboxane mimetic pulmonary vasoconstrictor U46619 and the increase in pulmonary arterial pressure (PAP) was measured. In beagle dogs, INS1009 was given by inhalation via face mask and TRE was given by continuous i.v. infusion; vasoconstriction was then induced by inhaled hypoxia with reduction of FIO2 to 0.10. Changes in the dog's right ventricular pulse pressure (RVPP) were measured using implanted telemetry probes. Blood samples were collected in rats and dogs immediately after the challenge to measure the plasma TRE concentration. Exposure of rats to inhaled INS1009 (0.5, 3.0 and 20.9 μg/kg) inhibited the U46619-induced increase in PAP at all doses up to 6 h with statistically significant inhibition up to 24 h with the pooled dose-response data. The concentration of TRE in the plasma at which PAP was reduced by 50% was approximately 60-fold lower for INS1009 (EC50 = 0.08 ng/mL) as compared to i.v. TRE (EC50 = 4.9 ng/mL). In dogs, INS1009 (2.7-80.9 μg/kg) inhibited the hypoxia-induced increase in RVPP at all doses up to 6 h with activity once again observed with the pooled dose-response of 10 μg/kg and higher at 24 h. The concentration of TRE in the plasma at which RVPP was reduced by 50% was approximately 550-fold lower for INS1009 (EC50 = 0.0075 ng/mL) as compared to i.v. TRE (EC50 = 4.1 ng/mL). These studies, in two species and by two different pulmonary vasoconstrictor challenges, demonstrate that inhaled INS1009 not only has long-acting vasodilatory effects but also that the local activity within the lung contributes to this response. Therefore, INS1009 may offer the opportunity to effect pulmonary vasodilation for long periods but with substantially lower systemic exposure than infused TRE.
Keywords: Dogs; Hexadecyl-treprostinil prodrug; Local lung effect; Pulmonary vasodilation; Rats; Treprostinil.
Copyright © 2018 The Authors. Published by Elsevier Ltd.. All rights reserved.
Similar articles
-
An overview of the biology of a long-acting inhaled treprostinil prodrug.Pulm Pharmacol Ther. 2020 Dec;65:102002. doi: 10.1016/j.pupt.2021.102002. Epub 2021 Feb 15. Pulm Pharmacol Ther. 2020. PMID: 33596473 Review.
-
Inhaled Treprostinil-Prodrug Lipid Nanoparticle Formulations Provide Long-Acting Pulmonary Vasodilation.Drug Res (Stuttg). 2018 Nov;68(11):605-614. doi: 10.1055/s-0044-100374. Epub 2018 May 23. Drug Res (Stuttg). 2018. PMID: 29791923
-
Therapeutic administration of inhaled INS1009, a treprostinil prodrug formulation, inhibits bleomycin-induced pulmonary fibrosis in rats.Pulm Pharmacol Ther. 2018 Apr;49:95-103. doi: 10.1016/j.pupt.2018.01.012. Epub 2018 Feb 2. Pulm Pharmacol Ther. 2018. PMID: 29408757
-
Preclinical Pharmacology and Pharmacokinetics of Inhaled Hexadecyl-Treprostinil (C16TR), a Pulmonary Vasodilator Prodrug.J Pharmacol Exp Ther. 2017 Dec;363(3):348-357. doi: 10.1124/jpet.117.242099. Epub 2017 Sep 13. J Pharmacol Exp Ther. 2017. PMID: 28904003
-
The potential for inhaled treprostinil in the treatment of pulmonary arterial hypertension.Ther Adv Respir Dis. 2011 Jun;5(3):195-206. doi: 10.1177/1753465810397693. Epub 2011 Feb 7. Ther Adv Respir Dis. 2011. PMID: 21300738 Review.
Cited by
-
Effect of Inhalation Profile on Delivery of Treprostinil Palmitil Inhalation Powder.Pharmaceutics. 2023 Mar 14;15(3):934. doi: 10.3390/pharmaceutics15030934. Pharmaceutics. 2023. PMID: 36986795 Free PMC article.
-
Lipid Nanoparticles as Delivery Vehicles for Inhaled Therapeutics.Biomedicines. 2022 Sep 2;10(9):2179. doi: 10.3390/biomedicines10092179. Biomedicines. 2022. PMID: 36140280 Free PMC article. Review.
-
Safety, Tolerability, and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder for Pulmonary Hypertension: A Phase 1, Randomized, Double-Blind, Single- and Multiple-Dose Study.Adv Ther. 2022 Nov;39(11):5144-5157. doi: 10.1007/s12325-022-02296-x. Epub 2022 Sep 7. Adv Ther. 2022. PMID: 36070132 Free PMC article. Clinical Trial.
-
Group 3 Pulmonary Hypertension: From Bench to Bedside.Circ Res. 2022 Apr 29;130(9):1404-1422. doi: 10.1161/CIRCRESAHA.121.319970. Epub 2022 Apr 28. Circ Res. 2022. PMID: 35482836 Free PMC article. Review.
-
Strategies to Overcome Biological Barriers Associated with Pulmonary Drug Delivery.Pharmaceutics. 2022 Jan 27;14(2):302. doi: 10.3390/pharmaceutics14020302. Pharmaceutics. 2022. PMID: 35214039 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials